Summary:
A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects with Mild to Moderate Alzheimer’s Disease
Qualified Participants Must:
Male or female, aged 60-90 years
Diagnosis of probable Alzheimer's Disease
Qualified Participants May Receive:
Compensation for time and travel